Screener
Bioventus BVS Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by Bioventus in its filing.
Tagged under the XBRL concept us-gaap:LongTermInvestments.
The source filing: Bioventus’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:43 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001665988-26-000042
| Line item | June 27, 2026 | December 31, 2025 |
|---|---|---|
| Intangible assets, net | 351,046 | 368,419 |
| Operating lease assets | 4,225 | 5,122 |
| Deferred tax assets | 29,052 | 5,522 |
| Investment and other assets | 3,507 | 2,293 |
| Total assets | $673,346 | $683,559 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $20,196 | $10,928 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bioventus's equity method investments?
- Bioventus (BVS) reported equity method investments of $3.51M in Q2 2026.
- How has Bioventus's equity method investments changed year-over-year?
- Bioventus's equity method investments increased by 107.9% year-over-year, from $1.69M to $3.51M.
- What is the long-term trend for Bioventus's equity method investments?
- Over 5 years (2020 to 2025), Bioventus's equity method investments has grown at a -34.7% compound annual growth rate (CAGR), from $19.38M to $2.29M.
- What does equity method investments mean?
- Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.
Ask your AI about Bioventus's equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude